Ormeloxifene - Isotope Labelled Standards
References
FAQ's
References
- Bolger, James W., Process For Preparation Of Substituted 3,4-(Diphenyl)Chromans, Rexall Drug and Chemical Co., US3822287A, July 2, 1974
- Shivaraj, Anusha; Battula, Shireesha, Method development and validation of RP-HPLC method for the estimation of Ormeloxifene, International Journal of Applied Pharmaceutical Sciences and Research, Volume: 2, Issue: 3, Pages: 78-82, Journal, 2017
Frequently Asked Questions
Can Ormeloxifene impurities be removed?
It is challenging to remove all impurities in Ormeloxifene. However, measures help minimize impurity levels during the preparation process and ensure they are within acceptable limits defined by regulatory authorities.
What is the significance of analyzing Ormeloxifene impurities?
Analyzing Ormeloxifene impurities is significant to ensure the safety, efficacy, and quality of the medication by identifying, quantifying, and controlling unwanted substances that may have toxic or adverse effects on patients or interfere with the desired therapeutic action of Ormeloxifene.
How are Ormeloxifene impurities synthesized?
Ormeloxifene impurities synthesize through various mechanisms during preparation, including incomplete reactions, side reactions, and their presence in starting materials or reagents.
What are the temperature conditions required to store Ormeloxifene impurities?
Ormeloxifene impurities are stored at a regulated room temperature of 2-8°C or as specified on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.